Reference | Location | Time Period | Study Design | Study Population | Results |
Impact of birth canal cleansing with chlorhexidine on mother infections (Bakr et al., 2005) | Egypt | 01/2002-06/2002 | Quasi-experimental study | n = 4415 women & 4431 infants Intervention group (birth canal cleansing: n = 2287 mothers) Non-intervention phase (no birth canal cleansing: n = 2128 mothers) Birthing women | Differences in maternal hospital admissions (p = 0.09) and deaths (p = 0.88) due to infections were not statistically significant among the intervention and non-intervention groups |
CPAP (early nasal continuous positive airway pressure) therapy for pre-eclampsia (Guilleminault et al., 2007) | U.S.A | n/a | Prospective, longitudinal, before and after study | n = 12 Pregnant women with pre-eclampsia risk factors) | CPAP therapy does not prevent pre-eclampsia |
Effects on maternal mortality of antenatal and delivery services administered by trained TBAs (traditional birth attendants) (Jokhio et al., 2005) | Pakistan | 03/1998-10/1998 | Cluster-randomized controlled trial | n = 19,557 Intervention group (trained TBAs; n = 10,114 pregnant women from 3 subdistricts in rural Pakistan). Control group (no trained TBAs; n = 9443 pregnant women from 4 subdistricts in rural Pakistan) | There was no statistically significant reduction in maternal mortality between the two groups. “As compared to the control group, the intervention group had a cluster-adjusted odds ratio for maternal mortality of 0.74 (95% confidence interval, 0.45 to 1.23)” (Jokhio et al., 2005) |
Oral N-acetylcysteine therapy for early onset severe pre-eclampsia/ HELLP syndrome (Roes et al., 2006) | Netherlands | 01/1999-10/2001 | Randomized, double-blind, placebo-controlled trial | n = 38; Placebo group (n = 19); N-acetylcysteine group (n = 19) Pregnant women with severe pre-eclampsia and/or HELLP syndrome | Oral N-acetylcysteine administration does not stop the progression of early onset severe pre-eclampsia and/or HELLP syndrome |
Aspirin for preventing protein uric eclampsia (Rotchell et al., 1998) | Barbados | 07/1992-07/1994 | Randomized placebo-controlled trial | n = 3647; Aspirin group (n = 1822) Placebo group (n = 1825) Pregnant women attending antenatal care | There were low, not statistically significant, rates of protein uric pre-eclampsia in both the aspirin and placebo group. (2.2% and 2.5% of women in the aspirin and placebo groups, respectively, developed protein uric pre-eclampsia) |